All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.

The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. View funders.

2017-04-11T15:59:42.000Z

FDA Biologics License Application submitted for KTE-C19 for transplant ineligible relapsed/refractory patients with Non-Hodgkin Lymphoma

Apr 11, 2017
Share:

Bookmark this article

On 31st March 2017, Kite Pharma completed its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for KTE-C19 (also known as axicabtagene ciloleucel) for transplant ineligible R/R aggressive NHL patients.

The BLA was completed subsequent to a rolling data submission, required as part of a Breakthrough Therapy Designation received in December 2015.

Results of the phase II ZUMA-1 trial (NCT02348216) were used to base the BLA on. KTE-C19 achieved an ORR of 82% and a CR rate of 54% for R/R aggressive NHL patients. Primary results of the trial were presented at the American Association for Cancer Research (AACR) 2017 Annual meeting, reported by the Lymphoma Hub this week.

  1. FDA Submission Completed for Axicabtagene Ciloleucel in NHL. 2017 Apr 01. http://www.onclive.com/web-exclusives/fda-submission-completed-for-axicabtagene-ciloleucel-in-nhl. [Accessed 2017 Apr 11].

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Your opinion matters

HCPs, what is your preferred format for educational content on the Lymphoma Hub?
26 votes - 5 days left ...

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox